← Eichor
Study identifier: NCT06871488 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

Condition: ADHD - Attention Deficit Disorder With Hyperactivity · Irritability · Aggression Childhood  ·  Sponsor: Milton S. Hershey Medical Center

PhasePhase 4
Planned participants136
Who can joinAll sexes, 7 Years to 12 Years
Healthy volunteersNo

About this study

Impulsive Aggression and chronic irritability (IACI) often occur together and are one of the most common reasons children present for behavioral health (BH) care. ADHD frequently associated with IACI as upwards of 50% of youth with ADHD manifest impairing IACI levels. IACI is the most common reason that children with ADHD are prescribed antipsychotics and admitted to inpatient BH units. Systematic dose optimization of CNS stimulants improves levels of IACI, reducing the need for these more intensive and burdensome treatments. However, response varies, with over half of children with ADHD showing meaningful improvement, upwards of 40% receiving minimal benefit and 3 to 10% exhibiting increased IACI levels. Symptom levels of ADHD or IACI and other demographic variables are of limited utility for predicting response, suggesting the need to move beyond symptoms in the search for treatment predictors. Youth with ADHD and IACI struggle with multiple aspects reinforcement learning (RL), defined as learning from interactions with the environment to reach a goal. Successful RL efforts tap multiple cognitive functions. In controlled laboratory tasks, youth with IACI and various BH disorders exhibit excessive behavioral and neural response to receiving reward (reward responsiveness), difficulty processing environmental cues to adapt behavior to meet a goal (set shifting/goal updating) and impaired ability to flexibly attend to relevant stimuli when blocked from a goal (frustrative nonre…

This description comes directly from the study's public registry record.

Talk to the study team

James G Waxmonsky, MD  ·  1-800-243-1455  ·  jwaxmonsky@pennstatehealth.psu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Penn State Health Dept of PsychiatryHershey, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06871488